Combined analysis of two randomised Phase II trials comparing the efficacy and safety of nintedanib versus sorafenib in Caucasian and Asian patients with advanced hepatocellular carcinoma

被引：0
|
作者：
Palmer, D. [1 ]
Meyer, T. [2 ]
Chao, Y. [3 ]
Deptala, A. [4 ]
Fartoux, L. [5 ]
Feng, Y. -H. [6 ]
Graham, J. [7 ]
Lin, D. -Y. [8 ,9 ]
Ma, Y. T. [10 ]
Peck-Radosavljevic, M. [11 ]
Ross, P. [12 ]
Ryoo, B. -Y. [13 ]
Yen, C. -J. [14 ]
Hocke, J. [15 ]
Vlassak, S. [16 ]
Wenz, A. [15 ]
Loembe, A. -B. [17 ]
Cheng, A. -L. [18 ]
机构：
[1] Univ Liverpool, Translat Med, Liverpool L69 3BX, Merseyside, England
[2] UCL Canc Inst, London, England
[3] Taipei Vet Gen Hosp, Taipei, Taiwan
[4] Minist Interior, Cent Clin Hosp, Warsaw, Poland
[5] Hop St Antoine, F-75571 Paris, France
[6] Chi Mei Med Ctr, Tainan, Taiwan
[7] Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland
[8] Chang Gung Mem Hosp, Guishan, Taiwan
[9] Chang Gung Univ, Guishan, Taiwan
[10] Univ Birmingham, Sch Canc Sci, Birmingham, W Midlands, England
[11] Med Univ Wien, Vienna, Austria
[12] Kings Coll Hosp NHS Fdn Trust, London, England
[13] Asan Med Ctr, Seoul, South Korea
[14] Natl Cheng Kung Univ Hosp, Tainan 70428, Taiwan
[15] Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany
[16] SCS Boehringer Ingelheim Comm V, Brussels, Belgium
[17] Boehringer Ingelheim BV, Alkmaar, Netherlands
[18] Natl Taiwan Univ Hosp, Taipei, Taiwan
来源：
ANNALS OF ONCOLOGY | 2015年 / 26卷
关键词：
D O I：
10.1093/annonc/mdv234.4
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PD-005
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Efficacy and safety of nintedanib (N) versus sorafenib (S) in Caucasian and Asian patients with advanced hepatocellular carcinoma (HCC): Pooled analysis of two randomized phase II trials.
    Meyer, Tim
    Palmer, Daniel H.
    Chao, Yee
    Choi, Caren
    Deptala, Andrzej
    Fartoux, Laetitia
    Feng, Yin-Hsun
    Graham, Janet Shirley
    Hocke, Julia
    Kim, Tae-You
    Lin, Deng-Yn
    Ma, Yuk Ting
    Peck-Radosavljevic, Markus
    Ross, Paul J.
    Ryoo, Baek-Yeol
    Wenz, Arne
    Yen, Chia-Jui
    Loembe, Arsene-Bienvenu
    Cheng, Ann-Lii
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [2] Efficacy and safety of nintedanib vs sorafenib in Asian patients with advanced hepatocellular carcinoma (HCC): A randomised Phase II trial
    Yen, C.
    Kim, T. Y.
    Feng, Y. H.
    Chao, Y.
    Lin, D. Y.
    Studeny, M.
    Hocke, J.
    Huang, D. C. L.
    Ryoo, B. Y.
    Cheng, A. L.
    [J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 : S612 - S612
  • [3] Randomized phase II trial comparing the efficacy and safety of nintedanib versus sorafenib in patients with advanced hepatocellular carcinoma (HCC)
    Palmer, Daniel H.
    Ma, Yuk Ting
    Peck-Radosavljevic, Markus
    Ross, Paul J.
    Graham, Janet Shirley
    Fartoux, Laetitia
    Deptala, Andrzej
    Wenz, Arne
    Hocke, Julia
    Loembe, Arsene-Bienvenu
    Meyer, Tim
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [4] mRECIST to predict survival in advanced hepatocellular carcinoma: Analysis of two randomised phase II trials comparing nintedanib vs sorafenib
    Meyer, Tim
    Palmer, Daniel H.
    Cheng, Ann-Lii
    Hocke, Julia
    Loembe, Arsene-Bienvenu
    Yen, Chia-Jui
    [J]. LIVER INTERNATIONAL, 2017, 37 (07) : 1047 - 1055
  • [5] Efficacy and safety of nintedanib versus sorafenib in Asian patients with advanced hepatocellular carcinoma (HCC): A randomized phase II trial.
    Cheng, Ann-Lii
    Yen, Chia-Jui
    Kim, Tae-You
    Feng, Yin-Hsun
    Chao, Yee
    Lin, Deng-Yn
    Loembe, Arsene-Bienvenu
    Hocke, Julia
    Choi, Caren
    Ryoo, Baek-Yeol
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [6] mRECIST to predict survival in advanced hepatocellular carcinoma: Analysis of two randomized phase II trials comparing nintedanib versus sorafenib
    Meyer, Tim
    Palmer, Daniel H.
    Cheng, Ann-Lii
    Hocke, Julia
    Loembe, Arsene-Bienvenu
    Yen, Chia-jui
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [7] A Phase I/Randomized Phase II Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Nintedanib versus Sorafenib in Asian Patients with Advanced Hepatocellular Carcinoma
    Yen, Chia-Jui
    Kim, Tae-You
    Feng, Yin-Hsun
    Chao, Yee
    Lin, Deng-Yn
    Ryoo, Baek-Yeol
    Huang, Dennis Chin-Lun
    Schnell, David
    Hocke, Julia
    Loembe, Arsene-Bienvenu
    Cheng, Ann-Lii
    [J]. LIVER CANCER, 2018, 7 (02) : 165 - 178
  • [8] A multicentre, open-label, phase-I/randomised phase-II study to evaluate safety, pharmacokinetics, and efficacy of nintedanib vs. sorafenib in European patients with advanced hepatocellular carcinoma
    Palmer, D. H.
    Ma, Y. T.
    Peck-Radosavljevic, M.
    Ross, P.
    Graham, J.
    Fartoux, L.
    Deptala, A.
    Studeny, M.
    Schnell, D.
    Hocke, J.
    Loembe, A-B.
    Meyer, T.
    [J]. BRITISH JOURNAL OF CANCER, 2018, 118 (09) : 1162 - 1168
  • [9] A multicentre, open-label, phase-I/randomised phase-II study to evaluate safety, pharmacokinetics, and efficacy of nintedanib vs. sorafenib in European patients with advanced hepatocellular carcinoma
    D. H. Palmer
    Y. T. Ma
    M. Peck-Radosavljevic
    P. Ross
    J. Graham
    L. Fartoux
    A. Deptala
    M. Studeny
    D. Schnell
    J. Hocke
    A-B. Loembé
    T. Meyer
    [J]. British Journal of Cancer, 2018, 118 : 1162 - 1168
  • [10] Efficacy and safety of sorafenib in elderly patients with advanced hepatocellular carcinoma
    Marta, Guilherme Nader
    da Fonseca, Leonardo G.
    Braghiroli, Maria Ignez
    Moura, Fernando
    Hoff, Paulo M.
    Sabbaga, Jorge
    [J]. CLINICS, 2021, 76 : 1 - 6
12345